Two-Year Effects of Semaglutide in Adults with Overweight or Obesity: the STEP 5 Trial

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term treatment of adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes. The co-primary endpoints were the percentage change in body weight and achievement of weight loss of ≥5% at week 104. Efficacy was assessed among all randomized participants re

Universal Semaglutide Access Could Save 28 Million Lives in 5 Years, Study Finds – RamaOnHealthcare

Key TakeawaysUniversal semaglutide access could reduce all-cause mortality by 7.41%, saving 28 million lives over five years.The study projects a 21.9%

STEP UP: Higher Semaglutide Doses Yield Greater Weight Loss in Obesity

Semaglutide 7.2 mg shows promising results, achieving a mean 21% weight loss in obesity treatment.